ASCO25,pembrolizumab

Mashup Score: 2

10-Year KEYNOTE-016: Pembrolizumab Durable in MSI-H Tumors | GI Oncology Now - 6 day(s) ago

Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.

Source: www.gioncologynow.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- GiOncNow
  
  ⏰ Coming up at @ASCO #ASCO25: 10-year survival outcomes of KEYNOTE-016 and the benefit of #pembrolizumab for dMMR/MSI-H solid tumors: https://t.co/dd6L5bKMSx 👉 Watch Dr. Katherine M. Bever of @HopkinsMedicine present this new data in Hall D2 at 12:36 pm CDT tomorrow.